close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rezolute, Inc. - Common Stock (NV) (NQ:RZLT)

1.835 -0.015 (-0.81%)
Streaming Delayed Price Updated: 3:25 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rezolute, Inc. - Common Stock (NV)

< Previous 1 2 3 4 5 6 Next >
News headline image
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Why Aclarion Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket ↗
Shares of Aclarion, Inc. (NASDAQ: ACON) shares rose sharply in pre-market trading after the company was granted U.S. patent #11844601 for "MR SPECTROSCOPY SYSTEM FOR DIAGNOSING PAINFUL AND NON-PAINFUL... 
Via Benzinga
Topics Intellectual Property
News headline image
Analyst Expectations for Rezolute's Future ↗
 
Via Benzinga
News headline image
Expert Ratings for Rezolute ↗
 
Via Benzinga
News headline image
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
Plans to report topline data mid-second quarter 2024 
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"
Dallas, Texas--(Newsfile Corp. - November 24, 2023) - Stonegate Healthcare Partners highlights a unique opportunity in its report, "Black Friday... 
Via Newsfile
News headline image
Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Reports First Quarter Fiscal 2024 Results
From Rezolute, Inc.
Via GlobeNewswire
News headline image
What 4 Analyst Ratings Have To Say About Rezolute ↗
 
Via Benzinga
News headline image
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism 
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday, 369 companies set new 52-week lows. 
Via Benzinga
News headline image
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023 
From Rezolute, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Rezolute to Participate in Upcoming Investor Conferences in September
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute And 2 Other Penny Stocks Insiders Are Aggressively Buying ↗
The Dow Jones closed lower by over 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
News headline image
Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease
Dallas, Texas--(Newsfile Corp. - June 1, 2023) - Stonegate Healthcare Partners (SHP), a healthcare... 
Via Newsfile
News headline image
Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress
The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023 
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
RZ402 is an oral therapy being developed as a potential alternative to anti-vascular growth factor (anti-VEGF) injections into the eye 
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert
Conference call and webcast to be held on Wednesday, March 22 at 4:30 pm EDT 
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress
From Rezolute, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye 
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday, 297 companies reached new 52-week lows. 
Via Benzinga
News headline image
Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute to Present at the Jefferies London Healthcare Conference
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  During Friday, 125 stocks hit new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today